Research programme: selective androgen receptor modulators - Bristol-Myers Squibb/Ligand

Drug Profile

Research programme: selective androgen receptor modulators - Bristol-Myers Squibb/Ligand

Alternative Names: BMS 564929; BMS 665139

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Ligand Pharmaceuticals
  • Class Hydantoins
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Muscular atrophy

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Muscle-wasting in USA (PO)
  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
  • 15 Oct 2007 Bristol-Myers Squibb's SARM programme licensed to Pharmacopeia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top